Memory Pharmaceuticals’ Phase IIa study of MEM 1003 in acute mania in bipolar disorder, based on primary and secondary outcome measures in the trial, did not prove effective. The multi-center, double-blind, randomized, placebo-controlled study evaluated the safety and efficacy of MEM 1003 for the treatment of acute mania in bipolar disorder in 84 subjects. The primary outcome measure was a comparison of the percentage of subjects in the placebo and MEM 1003 treatment groups with at le...